See more : The Shimizu Bank, Ltd. (8364.T) Income Statement Analysis – Financial Results
Complete financial analysis of Celcuity Inc. (CELC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celcuity Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TUGA Innovations, Inc. (TUGA.CN) Income Statement Analysis – Financial Results
- Styrenix Performance Materials Limited (STYRENIX.BO) Income Statement Analysis – Financial Results
- First Tractor Company Limited (601038.SS) Income Statement Analysis – Financial Results
- Aprendere Skolor AB (publ) (APRNDR.ST) Income Statement Analysis – Financial Results
- Trevena, Inc. (TRVN) Income Statement Analysis – Financial Results
Celcuity Inc. (CELC)
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| Gross Profit | -142.77K | -210.92K | -303.24K | -385.59K | -339.00K | -223.04K | -104.70K | -73.06K | -58.38K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 60.59M | 35.29M | 25.76M | 7.68M | 6.27M | 6.33M | 4.98M | 3.06M | 2.01M |
| General & Administrative | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.52K | 263.66K | 250.09K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Cost & Expenses | 66.23M | 39.39M | 28.36M | 9.56M | 7.81M | 7.93M | 5.95M | 3.33M | 2.26M |
| Interest Income | 2.45M | 1.13M | 13.26K | 82.11K | 446.10K | 448.83K | 152.88K | 18.02K | 268.00 |
| Interest Expense | 0.00 | 2.11M | 1.26M | 120.00 | 159.00 | 111.00 | 451.66K | 0.00 | 0.00 |
| Depreciation & Amortization | 142.77K | 210.92K | 303.24K | 385.59K | 339.00K | 223.04K | 104.70K | 73.06K | 58.38K |
| EBITDA | -58.31M | -39.18M | -28.05M | -9.17M | -7.47M | -7.71M | -5.85M | -3.26M | -2.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -66.23M | -39.39M | -28.36M | -9.56M | -7.81M | -7.93M | -5.95M | -3.33M | -2.26M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.45M | -978.95K | -1.25M | 81.99K | 445.94K | 451.72K | -298.79K | 18.02K | 268.00 |
| Income Before Tax | -63.78M | -40.37M | -29.61M | -9.47M | -7.36M | -7.48M | -6.25M | -3.31M | -2.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 978.95K | 959.12K | -385.47K | -338.84K | 451.83K | 48.18K | 0.00 | 0.00 |
| Net Income | -63.78M | -41.35M | -30.56M | -9.09M | -7.02M | -7.48M | -6.25M | -3.31M | -2.26M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| EPS Diluted | -2.69 | -2.68 | -2.28 | -0.89 | -0.69 | -0.74 | -0.84 | -0.49 | -0.36 |
| Weighted Avg Shares Out | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
| Weighted Avg Shares Out (Dil) | 23.68M | 15.42M | 13.38M | 10.27M | 10.23M | 10.12M | 7.46M | 6.72M | 6.31M |
Why Celcuity (CELC) Might Surprise This Earnings Season
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
Celcuity to Participate in Cowen's 44th Annual Health Care Conference
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Celcuity Inc. (CELC) Q3 2023 Earnings Call Transcript
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
Source: https://incomestatements.info
Category: Stock Reports